Juan Carmona, MD
Family Medicine · Cape Coral, FLNPI 1083153761
Payments from drug & device makers
Across 337 payments — averaging $2816.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$825K
- Novartis$91K
- Astrazeneca UK Limited$29K
- GSK$764
- AbbVie$631
- Sumitomo Pharma America, Inc.$440
- plus $3K from 26 others
What the payments were for
- Travel & lodging$1,39319%
- Food & beverage$5,86581%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $825,222 |
| Novartis | 19 | $90,501 |
| Astrazeneca UK Limited | 7 | $28,937 |
| GSK | 45 | $764 |
| AbbVie(2 entities) | 35 | $631 |
| Sumitomo Pharma America, Inc. | 17 | $440 |
| Lilly USA, LLC | 23 | $406 |
| Amgen | 35 | $329 |
| Merck | 17 | $317 |
| Novo Nordisk | 18 | $301 |
| Boehringer Ingelheim | 11 | $219 |
| Dexcom, Inc. | 8 | $213 |
| Redhill Biopharma Inc. | 10 | $164 |
| Pfizer | 7 | $119 |
| Sunovion Pharmaceuticals Inc. | 3 | $61 |
| Bayer | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Axonics, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Exact Sciences | 1 | $30 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 2 | $26 |
| Mannkind Corporation | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$949,087 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 299 | $438,607 |
| MounjaroTirzepatide | 334 | $415,732 |
| FarxigaDapagliflozin Propanediol | 218 | $290,746 |
| EliquisApixaban | 210 | $279,115 |
| OzempicSemaglutide | 162 | $183,506 |
| JanuviaSitagliptin Phosphate | 121 | $166,635 |
| LinzessLinaclotide | 100 | $134,460 |
| ZenpepLipase/Protease/Amylase | 96 | $126,931 |
| XareltoRivaroxaban | 89 | $126,585 |
| GemtesaVibegron | 107 | $115,270 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 156 | $111,246 |
| GlyxambiEmpagliflozin/Linagliptin | 83 | $103,315 |
| Dexlansoprazole DrDexlansoprazole | 257 | $97,692 |
| TrulicityDulaglutide | 69 | $93,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $79,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $219 | $575,987412 claims |
| Lilly USA, LLCMounjaro, Trulicity | $406 | $509,574403 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $825,222 | $465,148520 claims |
| PfizerEliquis | $119 | $279,115210 claims |
| MerckJanuvia, Janumet Xr, Belsomra, Janumet | $317 | $267,278237 claims |
| Novo NordiskOzempic, Rybelsus | $301 | $213,835175 claims |
| AbbVieLinzess, Creon | $631 | $175,667142 claims |
| Aimmune Therapeutics, Inc.Zenpep | $30 | $126,93196 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $440 | $115,270107 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $764 | $96,002128 claims |
| NovartisEntresto | $90,501 | $60,39344 claims |
| AmgenProlia | $329 | $55,03631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Cape Coral
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.